The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Nurix Therapeutics Inc. (NASDAQ:NRIX) is one of the 9 Stocks Winning by Double Digits.

Nurix Therapeutics extended its gains to an 8th straight session on Thursday, touching a new 52-week high, as investors resumed buying positions following an earlier partnership with Roche for the co-development of a blood cancer treatment.

In intra-day trading, the stock climbed to a record high of $23.09 before trimming gains to end the day just up by 16.37 percent at $22.46 apiece.

Photo by Tima Miroshnichenko on Pexels

In a statement, Nurix Therapeutics Inc. (NASDAQ:NRIX) said that it joined forces with Roche to develop and commercialize bexobrutideg, a potential best-in-class oral degrader of Bruton's tyrosine kinase (BTK).

According to the two parties, the collaboration encompasses a comprehensive clinical development plan spanning malignant hematology, immunology and neurology intended to explore the full clinical potential of BTK degradation across diverse patient populations. In addition to the Phase 2 and Phase 3 trials in chronic lymphocytic leukemia, the collaboration plans to pursue multiple label-enabling studies across a range of malignant hematology indications as monotherapy and in combination regimens,  and expand development into immune-mediated diseases, including Phase 2 trials in MS and CSU.

"Partnering with Roche, a world leader in the treatment of B-cell malignancies, positions Nurix to fully realize the potential of bexobrutideg across multiple indications in oncology, immunology, and neurology," Nurix Therapeutics Inc. (NASDAQ:NRIX) President and CEO Arthur Sands said.

As part of the agreement, Nurix Therapeutics Inc. (NASDAQ:NRIX) is set to receive $700 million in upfront cash payments and is eligible to receive up to $2.3 billion upon milestone achievement.

While we acknowledge the potential of NRIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.